Posted by Michael Wonder on 01 Sep 2025
PHARMAC confirms continued access to Comirnaty COVID-19 vaccine
1 September 2025 - PHARMAC has secured a new supply agreement with Pfizer to continue funding the Comirnaty brand of COVID-19 vaccine.
This means Comirnaty will remain the main funded vaccine in New Zealand from 1 February 2026 through to at least 30 September 2027, with options to extend until 2029.
